Aeglea Biotherapeutics, Inc. (AGLE)
| Market Cap | 215.04M |
| Revenue (ttm) | 15.10M |
| Net Income (ttm) | -68.07M |
| Shares Out | 49.32M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,001 |
| Open | 4.47 |
| Previous Close | 4.47 |
| Day's Range | 4.28 - 4.51 |
| 52-Week Range | 3.47 - 8.79 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 13.63 (+212.6%) |
| Earnings Date | n/a |
About AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeli...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 13.63, which is an increase of 212.61% from the latest price.
News
Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency
AUSTIN, Texas, Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...
3 Biotech Stocks That Sank: Are Any a Bad-News Buy?
At least one of the three could be in store for better news in the future.
Why Aeglea BioTherapeutics Stock Is Way Down Today
MIxed phase 3 clinical trial results are making investors nervous.
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with ...
AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with A...
AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors
AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE S...
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...
Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel
AUSTIN, Texas, July 15, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzi...
AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Trea...
AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of...
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people w...
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginas...
AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Argi...
AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...